It’s Beyond The Food: Non-Diet Health Coaching · Stephanie Dodier

429-GLP-1: The Non-Diet Coaching Approach When You Feel Like Weight Loss is Everywhere

July 21, 2025·49 min·5 clips
Stephanie Dodier starts with the current moment, where GLP-1 medications like Ozempic and Vagovi are no longer fringe and are showing up in ordinary coaching and care conversations. She names the tension for anti-diet, non-diet, and weight-neutral professionals right away. The issue is not only the medication itself. The issue is how coaches think about GLP-1 and how to stay aligned with values while clients are asking real questions. She lays out the non-diet frame she wants coaches to use. That frame is about support, informed consent, and helping people think clearly rather than taking a side reflexively. The episode spends time on the practical work of holding the conversation without sliding into shame, panic, or sales language. Dodier keeps the focus on how a coach can be useful when a client is already considering GLP-1 or is surrounded by pressure to use it. From there she moves into the research she considers most relevant. She says GLP-1 medications do produce weight loss, but that the loss usually plateaus after about one year. She describes a range of roughly 8 to 21 percent body-weight loss over a period and says the effect depends on the drug manufacturer. She also emphasizes that people generally need to keep taking the medication to maintain the loss. That matters in her view because it is not always made clear in marketing or public conversation. She goes further into the limits of the evidence. The longest trial she cites runs to two years, which means there is still no full long-term picture of what happens beyond that. She notes that the two-year data already suggest some beginning regain even while people remain on medication. The episode treats that uncertainty as central, not incidental. Long-term outcomes matter if the goal is honest guidance rather than a short-term headline. Dodier also spends time on side effects. She says 74 percent of users experience them, especially nausea and diarrhea, and she names more serious risks that can occur less often, including kidney issues, suicidal ideation, and intestinal blockage. The point is not alarm for its own sake. The point is that any serious conversation about GLP-1 has to include harms as well as benefits. She places this drug class inside a broader history of weight-loss medications that were once celebrated and later pulled back when longer-term evidence changed the story. That history gives the episode its caution. Dodier is not arguing that clients never choose GLP-1. She is arguing that coaches should understand the pattern, the pressure, and the tradeoffs before they respond. The tone stays direct and teaching-focused throughout. She speaks as someone who expects the listener to be competent, but also to need language for a conversation that can get emotionally noisy very quickly. Repetition is part of the method here. She restates the key ideas so they can land. She brings the discussion back to coaching practice whenever the topic starts drifting into general culture-war noise. The closing returns to the same core position: coaches should create a safe space for informed consent around GLP-1 and support bodily autonomy rather than body policing. The episode ends with an invitation to join her waitlist for the non-diet coaching certification.

As heard by us

A steady non-diet take on a topic coaches cannot sidestep.

Stephanie Dodier treats GLP-1 as a hard, values-heavy topic for non-diet coaches who are hearing about it from clients more often. She keeps the focus on informed consent, side effects, and bodily autonomy, while still making room for the reality that the medication is now…

Read the full review in PlayNext →

Why you'd press play

Press play if GLP-1 is showing up in your client conversations.

Read the full recommendation in PlayNext →
Listen to the show on